ENDEAVOUR unites 21 promising lung cancer specialists with internationally recognized experts to foster collaboration and improve patient outcomes Three-year program aims to promote excellence in research and enhance clinical knowledge At launch event in Madrid participants initiated four collaborative research projects which will be developed under expert guidance MADRID--(BUSINESS WIRE)--The ENDEAVOUR lung cancer program, a three-year initiative designed to advance lung cancer research and car

LIESTAL, Switzerland--(BUSINESS WIRE)--An epidemiological market study commissioned by Curatis Holding AG (SIX:CURN, “Curatis”) shows that the target patient group is substantially larger than previous estimates. In the US alone, over 150,000 patients suffer from peritumoral brain edema in association with malignant tumors. In previous clinical studies, human corticorelin (C-PTBE-01), demonstrated significant benefits in the treatment of PTBE. “The prospect of developing a potential blockbuster

MARSEILLE, France--(BUSINESS WIRE)--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) announced the voting results of its shareholders at the Annual General Meeting (“AGM”), which took place on May 22, 2025, in Marseille. All resolutions were voted. A total of 114 votes were cast out of a total of 43,447,237 shares giving right to 43,535,215 voting rights, representing a quorum of 47,14%. Following the approval of its shareholders at the Annual Gen

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year follow-up data from the Phase III STARGLO study. After a median follow-up of 24.7 months, data showed a 40% improvement in overall survival (OS) for patients treated with Columvi® (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin (GemOx) and median OS was not reached, compared to 13.5 months for Rituxan® (rituximab) plus GemOx (R-GemOx). Thes

Denver (May 22, 2025) — The Colorado Department of Public Health and Environment, the Denver Department of Public Health and Environment, and Denver International Airport (DEN) are notifying the public of a possible measles exposure at Denver International Airport and a nearby hotel. An out-of-state traveler with a confirmed case of measles traveled through Denver International Airport and stayed at the Quality Inn and Suites Denver International Airport while infectious. The individual arrived

Servier is continuing to add to its oncology pipeline, announcing on Friday a deal to acquire an experimental menin inhibitor from Chinese firm BioNova Pharmaceuticals that is currently in Phase I/II development for the treatment of acute leukaemias. While exact financial terms of the transaction were not disclosed, Servier will make a cash payment, with BioNova eligible for additional earn-outs.Claude Bertrand, Servier's executive vice president of R&D, called BioNova's asset — dubbed BN104 — "

The UK's National Institute for Health and Care Excellence (NICE) on Friday issued final draft guidance recommending CSL Vifor’s Filspari (sparsentan) to treat adults in England with primary IgA nephropathy.The favourable decision on the dual endothelin angiotensin receptor antagonist offers a new once-daily oral treatment option to more than 4200 eligible individuals, particularly those with a urine protein excretion of 1.0 g/day or more, or a urine protein-to-creatinine ratio of 0.75 g/g or mo

ATG-037, an oral small molecule CD73 inhibitor, in combination with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), achieved an overall response rate (ORR) of 36.4% and disease control rate (DCR) of 100% in checkpoint inhibitor (CPI)-resistant melanoma patients in the ongoing STAMINA-01 trial, with one patient maintaining a partial response (PR) and remained on treatment for over 2 years without any safety concerns. In CPI-resistant non-small cell lung cancer (NSCLC), the combination of ATG-

Gilead Sciences' efforts to move use of Trodelvy (sacituzumab govitecan-hziy) up the treatment ladder in metastatic triple-negative breast cancer (TNBC) gained a boost on Friday when the company announced another late-stage study success in the first-line setting.Having reported last month that the Phase III ASCENT-04/KEYNOTE-D19 trial of Trodelvy — paired with Merck & Co.'s PD-1 inhibitor Keytruda (pembrolizumab) — significantly extended progression-free survival (PFS) in people newly diagnosed

The FDA’s vaccine advisory panel unanimously recommended maintaining JN.1 lineage variants for the forthcoming respiratory virus season's COVID-19 vaccines.The agency’s Vaccines and Related Biological Products Advisory Committee (VRBPAC), which convened on Thursday, delivered its recommendation following a comprehensive assessment of current variant circulation patterns and nonclinical vaccine performance data. All nine participating members voted in favour of targeting newer strains of JN.1, al